Press monitoring
Medtronic Announces FDA Approval of Infuse® Bone Graft for Three New Spine Surgery Indications
11.12.2015 | Press monitoring
DUBLIN - December 11, 2015 - Medtronic plc (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of additional spine surgery indications for Infuse® Bone Graft. Upon receiving final labeling approval from the FDA, the company expects to begin marketing these expanded indications in early calendar year 2016. With this...
CRISPR-Cas9 helps uncover genetics of exotic organisms
11.12.2015 | Press monitoring
The simplicity of CRISPR-Cas9 gene editing will soon make studying the genes of any organism, from the simplest slime mold to the octopus, as easy as it now is to study the genes controlling development in standard lab animals such as nematodes, fruit flies, frogs and mice. A new study from the University of California, Berkeley, illustrates the...
ImmBio Initiates First-in-Human Studies of its Novel Pneumococcal Vaccine, PnuBioVax
10.12.2015 | Press monitoring
Cambridge, UK, 10 December 2015 / B3C newswire / --ImmunoBiology Ltd (“ImmBio” or the Company), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, today announces that it has initiated enrolment for a First-in-Human study of its novel vaccine (“PnuBioVax™”) against the...
300 million child-friendly antimalarial treatments supplied without profit by Novartis
9.12.2015 | Press monitoring
Basel, December 9, 2015 - Novartis announced today that it has reached a delivery milestone of 300 million pediatric antimalarial treatments supplied without profit since 2009, helping to reduce the disease burden for children in more than 30 malaria-endemic countries. Coartem ® Dispersible is the first artemisinin-combination therapy (ACT)...
US government approves transgenic chicken
9.12.2015 | Press monitoring
The US Food and Drug Administration (FDA) has approved a chicken genetically engineered to produce a drug in its eggs. The drug, Kanuma (sebelipase alfa), is a recombinant human enzyme marketed by Alexion Pharmaceuticals. It replaces a faulty enzyme in people with a rare, inherited condition that prevents the body from breaking down fatty...
Functional human liver cells grown in the lab
7.12.2015 | Press monitoring
In new research appearing in the journal Nature Biotechnology, an international research team led by The Hebrew University of Jerusalem describes a new technique for growing human hepatocytes in the laboratory. This groundbreaking development could help advance a variety of liver-related research and applications, from studying drug toxicity to...
Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the EU for the treatment of type 1 and 2 diabetes
4.12.2015 | Press monitoring
Bagsvaerd, Denmark, 4 December 2015 - Novo Nordisk today announced the submission to the European Medicines Agency of the Marketing Authorisation Application (MAA) for the approval of faster-acting insulin aspart. Faster-acting insulin aspart is a mealtime insulin for improved control of postprandial glucose excursions and has been developed for...
China clone factory scientist eyes human replication
4.12.2015 | Press monitoring
The Chinese scientist behind the world's biggest cloning factory has technology advanced enough to replicate humans, he told AFP, and is only holding off for fear of the public reaction. Boyalife Group and its partners are building the giant plant in the northern Chinese port of Tianjin, where it is due to go into production within the next...
Novavax Initiates Global Pivotal Phase 3 Trial of the RSV F Vaccine to Protect Infants via Maternal Immunization
3.12.2015 | Press monitoring
GAITHERSBURG, Md., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the enrollment of the first participant in a global pivotal Phase 3 clinical trial, known as Prepare(TM),...
AB Science announces publication of a significant response case with masitinib in a patient with c-KIT-mutated metastatic melanoma a patient with of c-KIT-mutated metastatic melanoma
2.12.2015 | Press monitoring
AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), today announces the publication of an article entitled "Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with...
